Functional Mitral Regurgitation Staging and its Relationship to Outcomes in the COAPT Trial

TY - JOUR

T1 - Functional Mitral Regurgitation Staging and its Relationship to Outcomes in the COAPT Trial

AU - COAPT Investigators

AU - Cavalcante, João L.

AU - Asch, Federico M.

AU - Garcia, Santiago

AU - Weissman, Neil J.

AU - Sorajja, Paul

AU - Zhou, Zhipeng

AU - Hahn, Rebecca T.

AU - Lindenfeld, Jo Ann

AU - Abraham, William T.

AU - Redfors, Björn

AU - Mack, Michael J.

AU - Stone, Gregg W.

N1 - Funding Information: The COAPT trial was sponsored by Abbott Vascular and was designed collaboratively by the principal investigators and the sponsor. Dr Cavalcante has received consulting fees from Abbott Vascular, Circle Cardiovascular Imaging, Boston Scientific, Medtronic, and Siemens Healthineers; has received speaker honoraria from Circle Cardiovascular Imaging, Medtronic, and Siemens Helthineers; and has received research grants from Abbott Vascular, Circle Cardiovascular Imaging, Boston Scientific, Medtronic, and Siemens Healthineers. Drs Asch and Weissman have institutional contracts with Abbott, Neovasc, Ancora, Mitralign, Medtronic, Boston Scientific, Edwards Lifesciences, Biotronik, and Livanova. Dr Garcia has received consulting fees from Edwards Lifesciences, Abbott Vascular, and Amedus; has received institutional research grants from Edwards Lifesciences, Abbott Vascular, Gore, Medtronic, and Boston Scientific; and has received proctoring fees from Edwards Lifesciences. Dr Sorajja has received research grants from Edwards Lifesciences, Boston Scientific, Medtronic, and Abbott Structural; has received consulting fees from Edwards Lifesciences, Boston Scientific, Medtronic, Abbott Structural, Amedus, Gore, and Cardionomics; has received speaker honoraria from Edwards Lifesciences, Boston Scientific, Medtronic, and Abbott Structural; and holds equity in Amedus. Dr Hahn has received speaker fees from Abbott Vascular, Baylis Medical, and Edwards Lifesciences; has institutional consulting agreements for which she receives no direct compensation with Abbott Vascular, Boston Scientific, Edwards Lifesciences, Medtronic, and Novartis; and holds equity with Navigate. Dr Lindenfeld has received research grant support from AstraZeneca; and has received consulting income from Abbott Vascular, AstraZeneca, CVRx, Edwards Lifesciences, Impulse Dynamics, Boehringer Ingelheim, VoluMetrix, and V-Wave. Dr Abraham has received research grant support from Abbott Vascular and the National Heart, Lung, and Blood Institute (National Institutes of Health grant 1 UG3/UH3 HL140144-01, August 1, 2018, to July 31, 2022, “Impact of Low Flow Nocturnal Oxygen Therapy on Hospital Readmission/Mortality in Patients With Heart Failure and Central Sleep Apnea [LOFT-HF]”); has received consulting income from Abbott Vascular; and has received speaker honoraria from Impulse Dynamics. Dr Redfors and Mr Zhou have received funding to their institution (no personal financial compensation) from Abbott. Dr Mack has served as co–primary investigator for the PARTNER (Placement of Transcatheter Aortic Valve) trial for Edwards Lifesciences and the COAPT trial for Abbott; and has served as study chair for the APOLLO (Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation) trial for Medtronic. Dr Stone has received speaker honoraria from Medtronic, Pulnovo, and Infraredx; has served as a consultant to Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Vectorious, Miracor, Neovasc, Abiomed, Ancora, Elucid Bio, Occlutech, CorFlow, Apollo Therapeutics, Impulse Dynamics, Cardiomech, Gore, Amgen, Adona Medical, Millennia Biopharma; has equity or options from Ancora, Cagent, Applied Therapeutics, the Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, and Xenter. Dr Stone's daughter is an employee of Medtronic. Dr Stone's employer, Mount Sinai Hospital, receives research support from Abbott, Abiomed, Bioventrix, Cardiovascular Systems, Phillips, Biosense Webster, Shockwave, Vascular Dynamics, Pulnovo, and V-Wave. Funding Information: The COAPT trial was sponsored by Abbott Vascular and was designed collaboratively by the principal investigators and the sponsor. Dr Cavalcante has received consulting fees from Abbott Vascular, Circle Cardiovascular Imaging, Boston Scientific, Medtronic, and Siemens Healthineers; has received speaker honoraria from Circle Cardiovascular Imaging, Medtronic, and Siemens Helthineers; and has received research grants from Abbott Vascular, Circle Cardiovascular Imaging, Boston Scientific, Medtronic, and Siemens Healthineers. Drs Asch and Weissman have institutional contracts with Abbott, Neovasc, Ancora, Mitralign, Medtronic, Boston Scientific, Edwards Lifesciences, Biotronik, and Livanova. Dr Garcia has received consulting fees from Edwards Lifesciences, Abbott Vascular, and Amedus; has received institutional research grants from Edwards Lifesciences, Abbott Vascular, Gore, Medtronic, and Boston Scientific; and has received proctoring fees from Edwards Lifesciences. Dr Sorajja has received research grants from Edwards Lifesciences, Boston Scientific, Medtronic, and Abbott Structural; has received consulting fees from Edwards Lifesciences, Boston Scientific, Medtronic, Abbott Structural, Amedus, Gore, and Cardionomics; has received speaker honoraria from Edwards Lifesciences, Boston Scientific, Medtronic, and Abbott Structural; and holds equity in Amedus. Dr Hahn has received speaker fees from Abbott Vascular, Baylis Medical, and Edwards Lifesciences; has institutional consulting agreements for which she receives no direct compensation with Abbott Vascular, Boston Scientific, Edwards Lifesciences, Medtronic, and Novartis; and holds equity with Navigate. Dr Lindenfeld has received research grant support from AstraZeneca; and has received consulting income from Abbott Vascular, AstraZeneca, CVRx, Edwards Lifesciences, Impulse Dynamics, Boehringer Ingelheim, VoluMetrix, and V-Wave. Dr Abraham has received research grant support from Abbott Vascular and the National Heart, Lung, and Blood Institute (National Institutes of Health grant 1 UG3/UH3 HL140144-01, August 1, 2018, to July 31, 2022, “Impact of Low Flow Nocturnal Oxygen Therapy on Hospital Readmission/Mortality in Patients With Heart Failure and Central Sleep Apnea [LOFT-HF]”); has received consulting income from Abbott Vascular; and has received speaker honoraria from Impulse Dynamics. Dr Redfors and Mr Zhou have received funding to their institution (no personal financial compensation) from Abbott. Dr Mack has served as co–primary investigator for the PARTNER (Placement of Transcatheter Aortic Valve) trial for Edwards Lifesciences and the COAPT trial for Abbott; and has served as study chair for the APOLLO (Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation) trial for Medtronic. Dr Stone has received speaker honoraria from Medtronic, Pulnovo, and Infraredx; has served as a consultant to Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Vectorious, Miracor, Neovasc, Abiomed, Ancora, Elucid Bio, Occlutech, CorFlow, Apollo Therapeutics, Impulse Dynamics, Cardiomech, Gore, Amgen, Adona Medical, Millennia Biopharma; has equity or options from Ancora, Cagent, Applied Therapeutics, the Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, and Xenter. Dr Stone’s daughter is an employee of Medtronic. Dr Stone’s employer, Mount Sinai Hospital, receives research support from Abbott, Abiomed, Bioventrix, Cardiovascular Systems, Phillips, Biosense Webster, Shockwave, Vascular Dynamics, Pulnovo, and V-Wave.

PY - 2022/9/12

Y1 - 2022/9/12

UR - http://www.scopus.com/inward/record.url?scp=85136277219&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2022.07.013

DO - 10.1016/j.jcin.2022.07.013

M3 - Letter

AN - SCOPUS:85136277219

SN - 1936-8798

VL - 15

SP - 1773

EP - 1775

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

IS - 17

ER -